Cargando…
Catridecacog: a breakthrough in the treatment of congenital factor XIII A-subunit deficiency?
Circulating factor XIII (FXIII) consists of two active (A) and two carrier (B) subunits in tetrameric form. Congenital FXIII deficiency is a rare autosomal-recessive trait that mostly results from an FXIII A-subunit deficiency. Classic coagulation assays, such as prothrombin time or activated partia...
Autor principal: | Korte, Wolfgang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4096448/ https://www.ncbi.nlm.nih.gov/pubmed/25031548 http://dx.doi.org/10.2147/JBM.S35395 |
Ejemplares similares
-
Use of Catridecacog in a patient with severe Factor XIII deficiency undergoing surgery
por: Sottilotta, Gianluca, et al.
Publicado: (2019) -
New developments in the management of congenital Factor XIII deficiency
por: Fadoo, Zehra, et al.
Publicado: (2013) -
Factor XIII Subunit A in the Skin: Applications in Diagnosis and Treatment
por: Paragh, Lilla, et al.
Publicado: (2017) -
How to Assess Founder Effect in Patients with Congenital Factor XIII Deficiency
por: Shahraki, Hojat, et al.
Publicado: (2020) -
Factor XIII in the Acute Care Setting and Its Relevance in Obstetric Bleeding
por: Duque, Patricia, et al.
Publicado: (2022)